Ieq Capital LLC Invests $14.14 Million in United Therapeutics Corporation $UTHR

Ieq Capital LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 26,102 shares of the biotechnology company’s stock, valued at approximately $14,143,000. Ieq Capital LLC owned approximately 0.06% of United Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in UTHR. BlackRock Inc. purchased a new position in United Therapeutics in the 2nd quarter valued at $2,868,735,000. Wellington Management Group LLP grew its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter worth $293,418,000. Avoro Capital Advisors LLC grew its holdings in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $513.12 on Friday. The firm has a market capitalization of $22.01 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 1.74 and a beta of 0.59. The company’s 50-day moving average is $533.08 and its two-hundred day moving average is $537.36. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.41 EPS. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on UTHR shares. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,185,729.06. The trade was a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 442,575 shares of company stock worth $239,326,330 over the last quarter. 8.60% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.